Business Context and Reporting Period
Company: Greenwich LifeSciences, Inc. (GLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy to prevent breast cancer recurrence. The company is currently conducting the Phase III Flamingo-01 clinical trial and has no commercial revenue.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,657,137) | $(2,744,780) |
| Net Loss Per Share (Basic/Diluted) | $(0.39) | $(0.21) |
| Operating Expenses | $5,725,754 | $2,768,750 |
| Research & Development | $5,207,564 | $2,271,148 |
| General & Administrative | $518,190 | $497,602 |
| Cash and Cash Equivalents (End of Period) | $10,505,435 | $2,749,959 |
| Net Cash Used in Operating Activities | $(4,702,498) | $(1,834,454) |
| Net Cash Provided by Financing Activities | $9,029,912 | $492,423 |
| Total Current Liabilities | $5,235,229 | $5,824,804 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss more than doubled to $5.66 million from $2.74 million year-over-year, driven primarily by a 129% increase in R&D expenses.
- R&D Expense Surge: R&D costs rose by $2.94 million to $5.21 million, attributed to increased accounts payable for clinical trial expenses.
- Capital Raise: The company significantly increased financing activity, raising net proceeds of $9.03 million via its At-The-Market (ATM) program in Q1 2026, compared to $0.49 million in Q1 2025. This involved selling 367,547 shares at an average price of $25.33.
- Liquidity Improvement: Cash balances increased by $4.33 million during the quarter, ending at $10.51 million, up from $6.18 million at year-end 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year due to recurring net losses and negative operating cash flows. Continued operations depend on obtaining additional capital.
- Capital Needs: The company expects to incur significant expenses for the foreseeable future to support clinical trials, regulatory approval, and commercialization infrastructure. Future funding will likely come from equity or debt sales.
- Internal Control Weaknesses: Disclosure controls and procedures were deemed ineffective as of March 31, 2026, due to material weaknesses including inadequate segregation of duties, insufficient written policies, and lack of appropriate accounting software.
- Subsequent Events: Between April 1 and April 15, 2026, the company sold an additional 12,215 shares via the ATM program for net proceeds of $310,664.
- Related Party Transactions: Significant reimbursements were submitted to management ($2.2 million in Q1 2026 vs. $0.7 million in Q1 2025), and family members of the CEO received cash and option compensation.
Investor Verification Checklist
- Cash Runway: Verify the projected burn rate against the $10.5 million cash balance to assess the timeline for the next capital raise.
- ATM Program Capacity: Review the remaining capacity under the ATM agreement with H.C. Wainwright and the current market price relative to the recent average offering price of $25.33.
- Internal Control Remediation: Monitor the progress of the plan to remediate material weaknesses in internal controls over financial reporting.
- Clinical Trial Progress: Confirm the status and enrollment rates of the Flamingo-01 Phase III trial, as R&D expenses are heavily tied to this program.
- Related Party Obligations: Review the nature of the $2.2 million in reimbursements to management and the $52,382 in accrued unreimbursed expenses.